Time Limits Restriction in Germany

Time Limits Restriction in Germany

2014 Value in health

Thivolet, M. | Soussi, I. | Kornfeld, A. | Toumi, M. | Volume: 17, Issue: 7, Pages: A431, Germany, Value,

In Germany, with the introduction of the Pharmaceutical Market Restructuring Act (AMNOG) in January 1st2011, pricing and reimbursement decisions for new drugs have been driven by the early benefit assessment (EBA). G-BA can decide to set or not a time limitation to the decision. The Objectives of this study were, first, to review the number of time-limited decisions over time and second, to identify drivers of these decisions.

https://www.doi.org/10.1016/j.jval.2014.08.1096; 10.1016/j.jval.2014.08.1096